These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37225259)

  • 1. C3 glomerulopathy.
    Mehdi A; Taliercio JJ
    Cleve Clin J Med; 2023 May; 90(6 suppl 1):e1-e4. PubMed ID: 37225259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent C3 glomerulopathy after kidney transplantation.
    Obata S; Vaz de Castro PAS; Riella LV; Cravedi P
    Transplant Rev (Orlando); 2024 Apr; 38(2):100839. PubMed ID: 38412598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.
    Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J
    Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease.
    Heiderscheit AK; Hauer JJ; Smith RJH
    Am J Med Genet C Semin Med Genet; 2022 Sep; 190(3):344-357. PubMed ID: 35734939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.
    Caravaca-Fontán F; Díaz-Encarnación MM; Lucientes L; Cavero T; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez A; Pérez de José A; Rabasco C; Rodado R; Fernández L; Pérez Gómez V; Ávila AI; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Rodríguez E; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; Cano-Megías M; González F; Shabaka A; López-Rubio ME; Fenollosa MÁ; Martín-Penagos L; Da Silva I; Alonso Titos J; Rodríguez de Córdoba S; Goicoechea de Jorge E; Praga M;
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1287-1298. PubMed ID: 32816888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement gene mutations in children with C3 glomerulopathy: do they affect the response to mycophenolate mofetil?
    Günay N; Dursun İ; Gökçe İ; Akbalık Kara M; Tekcan D; Çiçek N; Torun Bayram M; Koyun M; Dinçel N; Dursun H; Saygılı S; Yürük Yıldırım ZN; Yüksel S; Dönmez O; Yel S; Demircioğlu Kılıç B; Aydoğ Ö; Atmış B; Çaltık Yılmaz A; Bakkaloğlu SA; Aytaç MB; Taşdemir M; Kasap Demir B; Soylu A; Çomak E; Kantar Özşahin A; Kaçar A; Canpolat N; Yılmaz A; Girişgen İ; Akkoyunlu KB; Alpay H; Poyrazoğlu HM
    Pediatr Nephrol; 2024 May; 39(5):1435-1446. PubMed ID: 38041748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
    Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
    Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options.
    Bartoli G; Dello Strologo A; Grandaliano G; Pesce F
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
    Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
    Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable remission of C3 glomerulonephritis with mycophenolate mofetil.
    Lioufas N; Finlay M; Barbour T
    Nephrology (Carlton); 2017 Feb; 22 Suppl 1():36-39. PubMed ID: 28176473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases.
    Escudero-Saiz VJ; Gonzalez Á; García-Herrera A; Larque AB; Bomback AS; Morantes L; Martínez-Chillarón M; Ollé J; Guillén E; Xipell M; Molina-Andújar A; Rodríguez D; Cuadrado E; Cacho J; Arana C; Esforzado N; Bastida C; Poch E; Diekman F; Cucchiari D; Quintana LF; Blasco M
    Kidney Med; 2024 Jun; 6(6):100823. PubMed ID: 38741947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert Discussion on Challenges in C3G Diagnosis: A Podcast Article on Best Practices in Kidney Biopsies.
    Lafayette RA; Charu V
    Adv Ther; 2023 Dec; 40(12):5557-5566. PubMed ID: 37751024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
    Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
    Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C3 glomerulopathy and current dilemmas.
    Ito N; Ohashi R; Nagata M
    Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized C3 Mouse: A Novel Accelerated Model of C3 Glomerulopathy.
    Devalaraja-Narashimha K; Meagher K; Luo Y; Huang C; Kaplan T; Muthuswamy A; Halasz G; Casanova S; O'Brien J; Peyser Boiarsky R; McWhirter J; Gartner H; Bai Y; MacDonnell S; Liu C; Hu Y; Latuszek A; Wei Y; Prasad S; Huang T; Yancopoulos G; Murphy A; Olson W; Zambrowicz B; Macdonald L; Morton LG
    J Am Soc Nephrol; 2021 Jan; 32(1):99-114. PubMed ID: 33288630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.
    Xiao X; Pickering MC; Smith RJ
    Semin Thromb Hemost; 2014 Jun; 40(4):465-71. PubMed ID: 24799308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on C3 Glomerulopathy: A Complement-Mediated Disease.
    Caravaca-Fontán F; Lucientes L; Cavero T; Praga M
    Nephron; 2020; 144(6):272-280. PubMed ID: 32369815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the complement biomarker profile of C3 glomerulopathy.
    Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.
    Häffner K; Michelfelder S; Pohl M
    Pediatr Nephrol; 2015 Nov; 30(11):1951-9. PubMed ID: 25986912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum.
    Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C
    Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.